Supplementary Data from Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer

Suppl. Table 1: Characteristics of the TCGA cohort; Suppl. Table 2: Characteristics of cohort A. CIS= carcinoma in situ; Suppl. Table 3: Characteristics of cohort B Suppl. Fig. 1. Correlation of degree of DNA methylation at CpG site cg10183885 in the SLC16A3 gene region (see Suppl. Table 4) and MCT4 mRNA expression; Suppl. Fig. 2. Correlation of gene expression and protein expression in cohort B. Suppl. Fig. 3. Representative H&E (upper panel) and immunohistochemical images in matched bladder cancer samples (each column is one patient). CD8 was used to stain T cells (middle panel) in comparison with MCT4 expression (lower panel). Suppl. Fig. 4. Protein expression of MCT4 in benign urothelium, primary tumor tissue and lymph node metastases (cohort A). Suppl. Fig. 5. Protein expression in primary tumors according to tumor stage (left) and lymph node involvement (right) (cohort A).; Suppl. Fig. 6. MCT4 mRNA expression correlates with molecular subtypes in the TCGA cohort using the updated TCGA nomenclature (n=408); Suppl. Fig. 7. MCT4 gene expression does not correlate with overall survival in a cohort of patients undergoing neoadjuvant chemotherapy; Suppl. Fig. 8. Expression of MCT4 in urothelial carcinoma cell lines detected by Western Blot (A) and qPCR (B); Suppl. Fig. 9. Effect of MCT4 silencing on cell growth in hypoxic conditions determined by MTT assay. Suppl. Fig. 10. Effect of inhibition of MCT4 using siRNA on cell growth of the MCT4 negative cell line RT4 determined by MTT assay; Suppl. Fig 11. Effect of MCT4 silencing on cell growth in glucose free conditions determined by MTT assay; Suppl.Fig. 12. Effect of different concentrations of MCT4 specific antisense olignucleotide (ASO) on cell growth determined by MTT assay. Suppl. Fig. 13. Oxygen consumption rates at baseline (A), following glucose injection (B) and following oligomycin injection (C) in cell lines treated with control siRNA or MCT4 specific siRNAs.